Frantz M Berthaud
Frantz M Berthaud
Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia [0.03%]
复发或难治慢性淋巴细胞白血病的当代疗法
Mathias Castonguay,John F Seymour
Mathias Castonguay
Relapsed or refractory (RR) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) presents increasing therapeutic complexity in the era of targeted agents. Frontline use of covalent Bruton tyrosine kinase inhibitors (cBTKis) and...
Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4 [0.03%]
转移性去势抵抗性前列腺癌系统治疗的ASCO全程管理指南，第2026.1.4版
Mary-Ellen Taplin,Rahul A Parikh,R Bryan Rumble et al.
Mary-Ellen Taplin et al.
[Box: see text]Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert pa...
Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2 [0.03%]
多柔比星和盐酸迭茋唑烷酮对心脏功能纵向变化的影响：儿童肿瘤学组ALTE11C2研究报告
Erin M Mobley,David R Doody,Steven D Colan et al.
Erin M Mobley et al.
Purpose: Dexrazoxane has been associated with preservation of left ventricular (LV) systolic function in relatively small studies of long-term childhood cancer survivors. What remains less clear is whether this associatio...
Should Artificial Intelligence Direct Systemic Therapy Decisions in Pancreatic Cancer? [0.03%]
人工智能应在胰腺癌的系统治疗决策中发挥指导作用吗？
Gabriel A Brooks,Raghav Sundar
Gabriel A Brooks
Modernizing Drug Development for Exceptional Therapies in High‑Unmet Need Diseases: A Call for Pragmatism and Patient Centricity [0.03%]
面向高需求疾病的卓越治疗药物的现代化研发：实用主义与患者为中心理念的倡导
Elizabeth M Jaffee,Timothy A Yap
Elizabeth M Jaffee
Reply to: Therapeutic Strategy Concerns for BRAF V600E-Mutated Differentiated Thyroid Cancer [0.03%]
BRAF V600E突变分化型甲状腺癌治疗策略的商榷回复
Nabil F Saba,Nofisat Ismaila,Francis Worden et al.
Nabil F Saba et al.
Reply to: "Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration" and "NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002" [0.03%]
关于“特瑞普利单抗联合放化疗治疗食管鳞癌：有关耐受性和随访期的讨论”及“EC-CRT-002研究中NRF2通路状态和维持性免疫治疗暴露”的答复
Baoqing Chen,Zimeng Li,Xingyuan Cheng et al.
Baoqing Chen et al.
Importance of Inclusion of Representative Populations in Pivotal Clinical Trials: Zolbetuximab as an Example [0.03%]
纳入关键性临床试验的人群代表性的重要性——Zolbetuximab为例证
Youngwoo Cho,Axel-R Hanauske,Mark J Ratain
Youngwoo Cho